Research Overview
Our laboratory focuses on advancing regenerative medicine through cutting-edge research in cell membrane repair mechanisms, cancer biology, and therapeutic protein development. We bridge the gap between basic molecular science and clinical applications, with the ultimate goal of developing novel therapeutic strategies for treating various diseases and injuries.
"Advancing regenerative medicine through research in cell membrane repair, cancer biology, and therapeutic protein development."
Research Projects
MG53 Protein in Cell Membrane Repair
activeInvestigating the role of MG53 protein in cell membrane repair mechanisms and its therapeutic potential for treating various diseases including diabetes, cardiovascular disease, and acute lung injury.
Key Findings:
- MG53 protects against acute kidney injury
- Promotes wound healing and tissue regeneration
- Enhances cell survival under stress conditions
Collaborators: Dr. Jane Smith, Dr. John Doe
Funding: NIH R01 Grant
Cancer Biology & Tumor Suppressors
activeResearch on tumor suppressors in lung cancer and other solid tumors, with focus on drug resistance mechanisms and MG53's role in suppressing tumor progression.
Key Findings:
- MG53 suppresses tumor progression in non-small cell lung cancer
- Reduces stress granule formation in cancer cells
- Opens new therapeutic avenues for cancer treatment
Collaborators: Dr. Sarah Johnson
Funding: American Cancer Society
Regenerative Medicine & Bioinspired Hydrogels
activeDevelopment of innovative approaches to tissue repair and regeneration, including bioinspired hydrogels for controlled drug release and sustained delivery systems for therapeutic proteins.
Key Findings:
- Bioinspired hydrogels for controlled drug release
- Sustained delivery systems for therapeutic proteins
- Promising results for chronic wound treatment in diabetic patients
Collaborators: Dr. Michael Chen, Dr. Lisa Wang
Funding: NSF Grant
Translational Medicine & Protein Therapy
activeBridging basic science and clinical applications, with several therapeutic proteins and delivery systems moving toward clinical translation.
Key Findings:
- Recombinant human MG53 protein shows protective effects
- Protection against influenza virus infection
- Demonstrates translational potential for tissue injury treatment
Collaborators: Dr. Robert Kim, Dr. Maria Garcia
Funding: Industry Partnership